APA (7th ed.) Citation

P, H., J, B., MC, F., BP, R., & JM, B. (1997). Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats. The Journal of pharmacology and experimental therapeutics, 281(1), 208.

Chicago Style (17th ed.) Citation

P, Honore, Buritova J, Fournié-Zaluski MC, Roques BP, and Besson JM. "Antinociceptive Effects of RB101, a Complete Inhibitor of Enkephalin-catabolizing Enzymes, Are Enhanced by a Cholecystokinin Type B Receptor Antagonist, as Revealed by Noxiously Evoked Spinal C-Fos Expression in Rats." The Journal of Pharmacology and Experimental Therapeutics 281, no. 1 (1997): 208.

MLA (9th ed.) Citation

P, Honore, et al. "Antinociceptive Effects of RB101, a Complete Inhibitor of Enkephalin-catabolizing Enzymes, Are Enhanced by a Cholecystokinin Type B Receptor Antagonist, as Revealed by Noxiously Evoked Spinal C-Fos Expression in Rats." The Journal of Pharmacology and Experimental Therapeutics, vol. 281, no. 1, 1997, p. 208.